US FDA accepts Roche’s sBLA and grants priority review status for Tecentriq to treat NSCLC: Basel Wednesday, August 4, 2021, 12:00 Hrs [IST] Roche announced that the US Food and ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

The European Commission (EC) has approved a label extension for Roche’s Evrysdi (risdiplam) to include a tablet for people living with SMA.

Male health supplements like Nitric Boost Ultra are garnering the attention of men in their late 40s and early 50s alike. One ...

ProstaVive is a male health supplement that has been receiving much attention lately because it is said to address the ...

The study, led by the U.S. Centers for Disease Control and Prevention (CDC), found that people who took bismuth subsalicylate ...

Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat)CAMBRIDGE, Mass ...

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SM ...

A Texas bill, awaiting Governor Abbott's signature, mandates warning labels on foods with ingredients not approved for ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...